Christine Chung L.
Corporate Officer/Principal presso FIBROGEN, INC.
Patrimonio netto: 209 460 $ in data 30/04/2024
Posizioni attive di Christine Chung L.
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| FIBROGEN, INC. | Corporate Officer/Principal | 01/01/2007 | - |
FibroGen (China) Medical Technology Development Co. Ltd.
 FibroGen (China) Medical Technology Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd. is a biomedical technology company based in Beijing, China. FibroGen () is dedicated to developing new mechanisms of action or "best-in-class" innovative drugs and medical devices to meet the unmet clinical needs of Chinese patients. The Chinese company also provides a platform to report adverse events related to FibroGen roxadustat products. The company was founded in 2011. Christine Chung L. has been the CEO of the company since 2019. | Amministratore Delegato | 01/01/2019 | - |
Beijing Falikang Pharmaceutical Co. Ltd.
 Beijing Falikang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., Beijing Falikang Pharmaceutical Co. Ltd. is a pharmaceutical company that manufactures pharmaceutical products. Beijing Falikang Pharmaceutical Co. Ltd. is based in Beijing, China. Beijing Falikang Pharmaceutical Co. was acquired by FibroGen (China) Medical Technology Development Co. Ltd. on July 31, 2020 for $2.14 million. The Chinese company was founded in 2019. | Presidente | 27/09/2020 | - |
| FibroGen International (Hong Kong) Ltd. | Direttore/Membro del Consiglio | 01/01/2018 | - |
| FibroGen International (Cayman) Ltd. | Direttore/Membro del Consiglio | 01/01/2019 | - |
Storia della carriera di Christine Chung L.
Precedenti posizioni note di Christine Chung L.
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
eMed Technologies Corp.
 eMed Technologies Corp. Packaged SoftwareTechnology Services eMed Technologies Corp. developed medical software technologies. It combined PACS, image management, web-based results distribution and web communications into a solution that empowered radiologists to manage more procedures, improve service and gain a competitive edge. It was headquartered in Burlington, MA. | Corporate Officer/Principal | - | - |
Formazione di Christine Chung L.
| Harvard University | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 4 |
| Cina | 3 |
| Hong Kong | 2 |
Posizioni
| Corporate Officer/Principal | 2 |
| Director/Board Member | 2 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 4 |
| Technology Services | 2 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| Aziende private | 5 |
|---|---|
eMed Technologies Corp.
eMed Technologies Corp. Packaged SoftwareTechnology Services eMed Technologies Corp. developed medical software technologies. It combined PACS, image management, web-based results distribution and web communications into a solution that empowered radiologists to manage more procedures, improve service and gain a competitive edge. It was headquartered in Burlington, MA. | Technology Services |
FibroGen (China) Medical Technology Development Co. Ltd.
FibroGen (China) Medical Technology Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd. is a biomedical technology company based in Beijing, China. FibroGen () is dedicated to developing new mechanisms of action or "best-in-class" innovative drugs and medical devices to meet the unmet clinical needs of Chinese patients. The Chinese company also provides a platform to report adverse events related to FibroGen roxadustat products. The company was founded in 2011. Christine Chung L. has been the CEO of the company since 2019. | Health Technology |
Beijing Falikang Pharmaceutical Co. Ltd.
Beijing Falikang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., Beijing Falikang Pharmaceutical Co. Ltd. is a pharmaceutical company that manufactures pharmaceutical products. Beijing Falikang Pharmaceutical Co. Ltd. is based in Beijing, China. Beijing Falikang Pharmaceutical Co. was acquired by FibroGen (China) Medical Technology Development Co. Ltd. on July 31, 2020 for $2.14 million. The Chinese company was founded in 2019. | Health Technology |
| FibroGen International (Hong Kong) Ltd. | |
| FibroGen International (Cayman) Ltd. |
- Borsa valori
- Insiders
- Christine Chung L.
- Esperienza